🏛️ Verified NIH Record • Updated 2026-04-22

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (NCT06864169)

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).

Who can join: Review the eligibility criteria below.

Location: Yale New Haven Hospital ( Site 0375) — New Haven, Connecticut

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (41 Sites)

Showing the first 25 of 41 sites.

  • Yale New Haven Hospital ( Site 0375) — New Haven, Connecticut
  • Sibley Memorial Hospital ( Site 0372) — Washington D.C., District of Columbia
  • Mt Sinai Comprehensive Cancer Center ( Site 0345) — Miami Beach, Florida
  • St. Vincent Healthcare Frontier Cancer Center ( Site 0347) — Billings, Montana
  • Morristown Medical Center ( Site 0349) — Morristown, New Jersey
  • University Hospitals Cleveland Medical Center ( Site 0369) — Cleveland, Ohio
  • University of Virginia Cancer Center ( Site 0365) — Charlottesville, Virginia
  • University of Wisconsin Carbone Cancer Center ( Site 0348) — Madison, Wisconsin
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001) — Mar del Plata, Buenos Aires
  • Nefra Medical Care - CEMIC Saavedra ( Site 0008) — Buenos Aires, Buenos Aires F.D.
  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007) — Rosario, Santa Fe Province
  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006) — La Rioja,
  • Sunnybrook Research Institute ( Site 0044) — Toronto, Ontario
  • Princess Margaret Cancer Centre ( Site 0041) — Toronto, Ontario
  • Centre Hospitalier de l'Université de Montréal ( Site 0042) — Montreal, Quebec
  • FALP ( Site 0062) — Santiago, Region M. de Santiago
  • Centro de Estudios Clínicos SAGA ( Site 0064) — Santiago, Region M. de Santiago
  • Clínica UC San Carlos de Apoquindo ( Site 0066) — Santiago, Region M. de Santiago
  • Bradfordhill ( Site 0069) — Santiago, Region M. de Santiago
  • Centre François Baclesse ( Site 0085) — Caen, Calvados
  • Institut Regional du Cancer Montpellier ( Site 0084) — Montpellier, Herault
  • Gustave Roussy ( Site 0081) — Villejuif, Val-de-Marne
  • Pitie Salpetriere University Hospital ( Site 0082) — Paris,
  • Prince of Wales Hospital ( Site 0122) — Hksar,
  • Queen Mary Hospital ( Site 0121) — Hksar,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastrointestinal Cancer

Explore by condition: All Gastrointestinal Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗